Skip to content

Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults

Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults, a Single-Blind Randomized Crossover Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02822898
Acronym
MIHMoSA
Enrollment
12
Registered
2016-07-06
Start date
2016-06-30
Completion date
2016-08-31
Last updated
2016-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult Volunteers

Keywords

Maintenance, Intravenous solutions, Intravenous fluids, Tonicity, Potassium, Sodium, Fluid retention

Brief summary

The prescription of intravenous maintenance solutions - although widespread - lacks important data on the optimal sodium and potassium content, which has given rise to an important debate in the scientific literature. Our study compares two different infusion fluids in 12 healthy adult volunteers without renal failure in a single-blind randomized crossover design over two 48 hour periods during which subjects are not allowed to eat or drink. Fluid 1 is a premixed solution containing 54 mmol/L of sodium and 26 mmol/L of potassium; fluid 2 is sodium chloride 0.9% in glucose 5% with 40 mmol/L of potassium. Both solutions are administered at 25 mL/kg of ideal body weight, as recommended by current guidelines (NICE 174) and both solutions are widely used in daily clinical practice. The primary hypothesis is that isotonic maintenance solutions lead to more fluid retention than hypotonic fluids. Metabolism of both solutions is assessed by sequential analysis of urine and serum, clinical parameters and bioelectrical impedance analysis.

Interventions

DRUGNaCl 0.9% in Glucose 5% with 40mEq Potassium

NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h

Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h

Sponsors

Baxter Healthcare Corporation
CollaboratorINDUSTRY
University Hospital, Antwerp
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults, 18-70 years of age * BMI 17-45 kg/m². * Creatinine clearance \>60 ml/min (according to eGFR CKD-EPI formula).

Exclusion criteria

* Acute medical illness within 3 weeks of first study period * Chronic medication: under diuretic therapy or other chronic medication that interfere with urine output or induce urine retention. All chronic medication should be declared before being enrolled in the study. * Medical history: * cardiac failure, * malnourishment, * diabetes mellitus, * urological disease preventing spontaneous or complete emptying of the bladder, * any medical or non-medical issue preventing complaint-free fasting for 48 hours (e.g. active peptic ulcer, psychosis, substance abuse…) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Urine Output48hUrinary output over study period (as AUC).
Body weight48hBody weight over study period (as AUC), used as a back up parameter for urinary output.

Secondary

MeasureTime frameDescription
Amount of sodium retention / excretion (excreted sodium / administered sodium)48hSodium retention / excretion over study period (mean at 24 and 48h)
Number of episodes of hypokalemia (<3.5 mmol/L), hyponatremia (<135 mmol/L), hypernatremia (>145 mmol/L)48h
Change of sodium level from its baseline value.48hArea under the electrolyte concentration curve (baseline level is reference line)
Change of sodium and potassium level from its baseline value.48hArea under the electrolyte concentration curve (baseline level is reference line)

Other

MeasureTime frameDescription
Volume Regulatory Profile 3: urinary potassium (mmol/L)48hSequential changes in mean urinary potassium (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.
Acid-Base Profile 1: serum chloride (mmol/L)48hSequential changes in mean serum chloride (per fluid type) at T0-T12-T24-T36-T48.
Acid-Base Profile 2: serum apparent strong ion difference (mEq/L)48hSequential changes in mean serum apparent strong ion difference (per fluid type) at T0-T12-T24-T36-T48.
Acid-Base Profile 3: urinary anion gap (mmol/L)48hSequential changes in mean urinary anion gap (per fluid type). Urinary potassium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.
Osmoregulatory Profile 1: urinary volume (mL)48hSequential changes in mean urinary volume (per fluid type) at T0-T12-T24-T36-T48.
Other Electrolytes Profile 2: Red blood cell magnesium (mmol/L)48hSequential changes in mean red blood cell magnesium (per fluid type) at T0-T24-T48.
Cortisol (µg/dL)48hSerum cortisol as a measure of stress due to fasting.
Bioelectrical impedance analysis 1: Total body water48hSequential changes in mean total body water (per fluid type) at T0-T24-T48.
Bioelectrical impedance analysis : Extracellular volume48hSequential changes in mean extracellular volume (per fluid type) at T0-T24-T48.
Other Electrolytes Profile 1: Serum phosphate (mmol/L)48hSequential changes in mean serum phosphate (per fluid type) at T0-T24-T48.
Osmoregulatory Profile 2: urinary osmolality (mOsm/kg)48hSequential changes in mean urinary osmolality (per fluid type). Urinary osmolality is determined on a sample of every individual diuresis. Subjects urinate as the urge rises.
Osmoregulatory Profile 3: serum antidiuretic hormone (ADH) (pg/mL)48hSequential changes in mean serum ADH (per fluid type) at T0-T24-T48.
Osmoregulatory Profile 4: thirst score (scale 0-5)48hSequential changes in mean thirst score (per fluid type) at T0-T12-T24-T36-T48. The thirst score is a subjective score on a scale of 0-5.
Volume Regulatory Profile 1: urinary sodium (mmol/L)48hSequential changes in mean urinary sodium (per fluid type). Urinary sodium is determined on a sample of every individual diuresis. Subjects urinate as the urge rises. Urinary sodium is used to calculate the fractional excretion of sodium.
Volume Regulatory Profile 2: serum aldosterone (ng/dL)48hSequential changes in mean serum aldosterone (per fluid type) at T0-T24-T48.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026